Enlivex Therapeutics Ltd. (ENLV) Stock Score, Valuation & Financial Research

Enlivex Therapeutics Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ENLV

Enlivex Therapeutics Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 0.50. These figures are a research snapshot, not a buy or sell recommendation.

What Enlivex Therapeutics Ltd. does

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Enlivex is a clinical-stage immunotherapy company that operates a dual strategy combining the development of macrophage reprogramming therapeutics with a treasury model anchored in decentralized prediction markets infrastructure. The company does not currently generate commercial revenue from product sales and relies on capital raises and treasury asset appreciation to fund its operations.

Products and services

  • The company's primary product candidate is Allocetra™, a clinical-stage macrophage reprogramming immunotherapy platform designed to restore immune system homeostasis.

Brands and product families

  • Allocetra™ — The company's lead macrophage reprogramming immunotherapy platform. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary Allocetra™ immunotherapy platform Source

Business risks and research considerations

  • History of operating losses and uncertainty regarding future profitability Source
  • Dependence on clinical trial success and regulatory approval Source
  • Reliance on third-party manufacturers and service providers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ENLV financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.50
Market capitalization:
8.46M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD 4.11B
Free cash flow:
USD -10.48M
Cash:
USD 5.52M
Total debt:
USD 17.25M
EPS:
USD 583.27
P/E ratio:
0.0x

What stands out

  • Free cash flow is USD -10.48M, negative for the stored period.
  • The balance sheet shows USD 5.52M of cash versus USD 17.25M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 11.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ENLV

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ENLV fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is ENLV's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ENLV's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ENLV

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.